<DOC>
	<DOCNO>NCT01948271</DOCNO>
	<brief_summary>The purpose research study well understand whether trichuris suis ovum ( TSO ) ingest orally may safe effective treatment psoriasis .</brief_summary>
	<brief_title>Efficacy Study Trichuris Suis Ova Treat Chronic Plaque Psoriasis</brief_title>
	<detailed_description>This open-label study ass safety efficacy 16 week treatment 7500 trichuris suis ovum ( TSO 7500 ) give every 2 week ( total 8 dos ) treatment moderate-to-severe , chronic , plaque-type psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : 1 . Males female , 1875 year old 2 . Diagnosis stable plaque type psoriasis least 6 month prior baseline 3 . Baseline moderate severe psoriasis , define : 1 . Psoriasis cover body surface area ( BSA ) ≥10 % ; 2 . Physician 's global assessment ( PGA ) ≥3 , ; 3 . PASI ≥12 4 . Must good health judge PI , base medical history , physical examination , clinical laboratory 5 . In opinion PI , must candidate systemic therapy phototherapy psoriasis 6 . If woman , entry must one following : 1 . Postmenopausal , define 45 year age amenorrhea least 18 month , &gt; 45 year age amenorrhea &gt; 6 month serum follicle stimulate hormone ( FSH ) level &gt; 40 IU/mL , surgically postmenopausal ( bilateral oophorectomy ) 2. surgically sterile ( hysterectomy tubal ligation otherwise incapable pregnancy ) 3 . If heterosexually active , practice highly effective method birth control , include hormonal prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , doublebarrier method ( eg , condom , diaphragm , cervical cap , spermicidal foam , cream , gel ) , male partner sterilization duration participation study 2 month receive last administration study agent ; 4 . Not heterosexually active 7 . Women childbearing potential must negative pregnancy test ( urine serum ) prior randomization 8 . Agree avoid prolonged exposure natural sunlight tan bed phototherapy device duration study 9 . Agree avoid prohibit concomitant medication detail duration study 4 week prior baseline 10 . Negative stool culture 11 . Subject ability provide inform consent 12 . Subjects inhaled ophthalmic steroid allow 1 . Subjects know history intestinal parasitic infection , even adequately treat , past 5 year 2 . Subject receive antibiotic , antifungal antiparasitic medication last 2 week prior Screening and/or would potentially require study treatment period 3 . Subject history drug alcohol abuse within 6 month prior screen 4 . Subject evidence poor compliance medical advice instruction include diet medication 5 . Subject unable unwilling swallow study medication suspension 6 . Subject significant medical condition put subject risk study participation and/or reason consider Investigator unsuitable candidate receive TSO potentially put risk study procedures 7 . Subjects participate another clinical trial within 30 day screen trial and/or experimental treatment population 8 . White blood cell count ≤3,000/mm3 ( ≤3.0 x 109/L ) ≥14,000/mm3 ( ≥14 x 109/L ) 9 . Platelet count ≤ 100,000/μL ( ≤100 x 109/L ) 10 . Serum creatinine &gt; 2 x upper limit normal ( ULN ) 11 . Aspartate alanine aminotransferase &gt; 2 x ULN 12 . Total bilirubin &gt; 2 mg/dL ( 34 μmol/L ) 13 . Hemoglobin &lt; 9 g/dL 14 . Subjects currently take take past 30 day , reason , medication , opinion investigator , suppress immune response . This may include limited systemic steroid , azathioprine , cyclosporine , tacrolimus , mycophenolate mofetil , mycophenolic acid , etanercept , adalimumab , infliximab , ustekinumab , cimzia , biologic agent target cell cytokine immune system . 15 . Subjects refractory 2 biological agent plaque psoriasis therapy due lack efficacy 16 . Subjects currently take take past 2 week , topical steroid 17 . Subjects nonstable dose vitamin D analog past 30 day 18 . Subjects currently take take past 30 day medication likely improve psoriasis thus interfere evaluation . This may include , addition medication list , phototherapy , methotrexate , hydroxyurea , acitretin 19 . Subjects diagnosis inflammatory bowel disease ( ulcerative colitis Crohn 's disease ) irritable bowel syndrome 20 . Subjects HIV1/HIV2 antibody , hepatitis B surface antigen , hepatitis C antibody 21 . Subject receive nonsteroidal antiinflammatory drug within 2 week Baseline visit 3 consecutive day , except acetylsalicylic acid ≤350 mg/d allow 22 . Women intend become pregnant breastfeed planning breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Trichuris suis ovum</keyword>
	<keyword>T-lymphocytes</keyword>
</DOC>